CD289抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD289 mouse mAb (green) and negative control (red).    

  
  

The CD289 antibody targets the CD289 antigen, also known as Toll-like receptor 3 (TLR3), a member of the Toll-like receptor family. TLR3 is a transmembrane protein primarily expressed in immune cells, including dendritic cells, macrophages, and epithelial cells. It plays a critical role in innate immunity by recognizing double-stranded RNA (dsRNA), a molecular pattern associated with viral infections. Upon activation, TLR3 triggers signaling pathways that induce the production of pro-inflammatory cytokines and type I interferons, essential for antiviral responses.

CD289 antibodies are valuable tools in research for studying TLR3 expression, function, and signaling mechanisms. They are used in techniques like flow cytometry, immunohistochemistry, and Western blotting to detect TLR3 in cellular and tissue samples. Clinically, TLR3 dysregulation has been linked to autoimmune diseases, chronic inflammation, and cancer, making CD289 antibodies potential candidates for therapeutic development. For instance, modulating TLR3 activity with antibodies could help treat viral infections or enhance antitumor immune responses.

Recent studies also explore TLR3's role in vaccine adjuvants and its involvement in neuroinflammatory conditions. However, challenges remain in understanding tissue-specific TLR3 interactions and avoiding off-target effects. CD289 antibodies continue to aid in unraveling these complexities, offering insights into TLR3's dual role in protective immunity and pathological inflammation. Their applications bridge basic research and translational medicine, highlighting their importance in immunology and drug discovery.